StockData
Biogen Inc. logo

Biogen Inc. (BIIB) stock

BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3056% above fair value
$250.79−0.86 (-0.34%)

Close on Nov 17, 2026Market cap $37.07BP/E 107.2Yield –

Biogen total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Biogen's total debt was $6.29B at Dec 31, 2025. For fiscal 2025 it was $6.29B, down 0.1% from the year before. Over ten years it grew 75.3% a year on average. The highest annual figure on record is $8.57B in fiscal 2021.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$6.29B-0.1%
FY2024Dec 31, 2024$6.30B-9.3%
FY2023Dec 31, 2023$6.94B+10.5%
FY2022Dec 31, 2022$6.28B-26.7%
FY2021Dec 31, 2021$8.57B+14.2%
FY2020Dec 31, 2020$7.50B+0.1%
FY2019Dec 31, 2019$7.50B+24.9%
FY2018Dec 31, 2018$6.00B+187400.0%
FY2017Dec 31, 2017$3.20M-84.8%
FY2016Dec 31, 2016$21.10M-7.9%
FY2015Dec 31, 2015$22.90M+638.7%
FY2014Dec 31, 2014$3.10M-99.5%
FY2013Dec 31, 2013$571.39M-49.9%
FY2012Dec 31, 2012$1.14B+7.5%
FY2011Dec 31, 2011$1.06B-0.5%
FY2010Dec 31, 2010$1.07B-1.3%
FY2009Dec 31, 2009$1.08B-0.5%
FY2008Dec 31, 2008$1.09B–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$6.29B-26.6%
Q4 FY2024Dec 31, 2024$6.30B-16.1%
Q4 FY2023Dec 31, 2023$6.94B-7.4%
Q4 FY2022Dec 31, 2022$6.28B+4.7%
Q4 FY2021Dec 31, 2021$8.57B–
Q4 FY2020Dec 31, 2020$7.50B–
Q4 FY2019Dec 31, 2019$7.50B+227045.5%
Q4 FY2018Dec 31, 2018$6.00B+187400.0%
Q3 FY2018Sep 30, 2018$0-100.0%
Q2 FY2018Jun 30, 2018$0-100.0%
Q1 FY2018Mar 31, 2018$3.30M-99.4%
Q4 FY2017Dec 31, 2017$3.20M-84.8%
Q3 FY2017Sep 30, 2017$573.20M–
Q2 FY2017Jun 30, 2017$559.90M–
Q1 FY2017Mar 31, 2017$561.50M–
Q4 FY2016Dec 31, 2016$21.10M–

More Biogen figures

See a number that looks wrong?